MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7

SAN JOSE,Calif.,Jan. 8,2019 -- MGI,established in 2016,a company committed to building core tools and technology to lead life science,announced it has reached a new milestone of 1,000 MGI sequencers installed in 16 countries. MGI Chief Operating Officer Dr. Hui Jiang also announced the availability of MGI's early access program for its newest ultra-high-throughput genetic sequencer,MGISEQ-T7,during a presentation at China Focus@JPM Week on the eve of the 37th annual J.P. Morgan Healthcare Conference.

MGI's COO Dr. Jiang Hui at the 37th annual J.P. Morgan Healthcare

The MGISEQ-T7 vastly improves speed,throughput and flexibility of DNA sequencing by enabling simultaneous but independent operation of up to four flow cells in a single run. The innovative quad-flowcell platform allows multiple flow cells with different read lengths and applications to be processed separately at any time. Sequencing of PE150 takes less than 24 hours at full load to complete. The MGI proprietary technologies,including DNBseq™used in T7,deliver exceptionally high accuracy and improve efficiency through upgrades to the flowcell,fluidics,and biochemical and optical system. The platform can produce up to 6Tb of daily data,equivalent to up to 60 whole human genomes in a single day.

Ultra-high-throughput Genetic Sequencer MGISEQ-T7

MGI's technology improves the speed,efficiency and affordability of large population health projects. In the past,a 100,000-population-genome program would take four to six years to complete,but now using six MGISEQ-T7 sequencers such projects could be completed in just one year,at much lower cost.

The early access program supports collaboration on the development of genetic technologies and applications. It allows customization of instruments and reagents and innovative financial models. MGI is planning to expand this program internationally over the coming year. The MGI platform is gaining support around the world,with more than 135 publications using MGI sequencers and over 20 petabytes of data generated.

Proprietary Sequencing Technology MGISEQ/BGISEQ's Progress

Besides its sequencer product portfolio,MGI has developed a product portfolio of automated sample preparation workstations to meet the needs of ultra-high-throughput genomic sequencing. Dr. Jiang also introduced the MGISP workstations series of products for sample preparation,MegaBOLT series of products for accelerating bioinformatics analysis,and ZLIMS software system for lab management with NGS sequencing process.

MGISEQ-2000 Genetic Sequencer

At the J.P. Morgan Healthcare Conference,MGI also announced a global partnership with Paragon Genomics,a leader in amplicon-based target enrichment and library preparation solutions for next-generation sequencing (NGS) assays. MGI will distribute Paragon Genomics' CleanPlex® NGSPanels for use with MGI's sequencing platforms in all territories worldwide except the U.S.,and Paragon Genomics will distribute MGI's automated sample preparation workstation systems in the U.S. and Canada.

About MGI

MGI Tech Co.,Ltd. (MGI) is committed to enabling effective and affordable healthcare solutions for all. Based on its proprietary technology,MGI produces sequencing devices,equipment,consumables and reagents to support life science research,medicine and healthcare. MGI's multi-omics platforms include genetic sequencing,mass spectrometry and medical imaging. Providing real-time,comprehensive,life-long solutions,its missionis todevelop and promote advanced life science tools for future healthcare.

Photo - /20190107/2339802-1-a

Photo - /20190107/2339802-1-b

Photo - /20190107/2339802-1-c

Photo - /20190107/2339802-1-d